期刊文献+

HIV-Infection Reduction-Rates in Patients, on Antiretroviral Efficacy-Trial of a Nigerian Broad-Spectrum Antiviral Medicine (Antivirt<sup>®</sup>)

HIV-Infection Reduction-Rates in Patients, on Antiretroviral Efficacy-Trial of a Nigerian Broad-Spectrum Antiviral Medicine (Antivirt<sup>®</sup>)
在线阅读 下载PDF
导出
摘要 In verifying antiretroviral efficacy of a Nigerian broad spectrum antiviral medicine (Antivirt<span style="white-space:nowrap;"><sup>&#174;</sup></span>), the Nigerian Institute of Medical Research certified it safe by toxicological test on laboratory animals, before commencing treatment of three HIV/AIDS patients whose viral loads varied widely (millions, hundreds of thousands and thousands). To overcome errors associated with such wide differences in subject-classes, percentages of viral load-reductions were calculated instead of comparing their viral loads. After first month of the Antivirt<span style="white-space:nowrap;"><sup>&#174;</sup></span>-treatment, means of ranked viral loads of the patients significantly (P ≤ 0.05) increased from 10.00 ± 7.21 to 11.30 ± 5.51 (-41.03% infection-reduction rate) instead of reducing. From second month of the trial, their viral loads started to reduce, continuously, so that their infection-reduction rates have been increasing from that -41.03%, to -38.22% in the second month;23.98% in the third month;31.76% in the fourth month and 64.12% after the fifth month. In verifying antiretroviral efficacy of a Nigerian broad spectrum antiviral medicine (Antivirt<span style="white-space:nowrap;"><sup>&#174;</sup></span>), the Nigerian Institute of Medical Research certified it safe by toxicological test on laboratory animals, before commencing treatment of three HIV/AIDS patients whose viral loads varied widely (millions, hundreds of thousands and thousands). To overcome errors associated with such wide differences in subject-classes, percentages of viral load-reductions were calculated instead of comparing their viral loads. After first month of the Antivirt<span style="white-space:nowrap;"><sup>&#174;</sup></span>-treatment, means of ranked viral loads of the patients significantly (P ≤ 0.05) increased from 10.00 ± 7.21 to 11.30 ± 5.51 (-41.03% infection-reduction rate) instead of reducing. From second month of the trial, their viral loads started to reduce, continuously, so that their infection-reduction rates have been increasing from that -41.03%, to -38.22% in the second month;23.98% in the third month;31.76% in the fourth month and 64.12% after the fifth month.
作者 M. C. O. Ezeibe B. L. Salako F. I. O. Onyeachonam A. David O. O. Aina E. Herbertson M. E. Sanda I. J. Ogbonna E. Kalu N. U. Njoku M. I. Udobi C. A. Akpan M. C. O. Ezeibe;B. L. Salako;F. I. O. Onyeachonam;A. David;O. O. Aina;E. Herbertson;M. E. Sanda;I. J. Ogbonna;E. Kalu;N. U. Njoku;M. I. Udobi;C. A. Akpan(College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria;Nigerian Institute of Medical Research, Lagos, Nigeria)
出处 《World Journal of AIDS》 2020年第2期141-148,共8页 艾滋病(英文)
关键词 Antivirt<sup>®</sup> Opposite Charges’ Electrostatic Attraction Continuous Depletion Of HIV-Infection Loads Antivirt<sup>®</sup> Opposite Charges’ Electrostatic Attraction Continuous Depletion Of HIV-Infection Loads
  • 相关文献

二级参考文献3

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部